이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension (METH-FOCUS)

2026년 11월 11일 업데이트: Jeffrey Robinson, Oregon Health and Science University

Methamphetamine-Associated PAH: Early Therapy With Sotatercept - Feasibility and Outcomes in Clinical Use Study (METH-FOCUS)

The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by:

  • Echocardiographic measurements of pulmonary hypertension
  • Change in 6-minute walk distance (6MWD)
  • Change in categorization of disease (World Health Organization Functional Class, WHO FC)
  • Quality of life improvements

Participants will need to adhere to their standard PAH therapy as well as the prescribed sotatercept, as well as actively engaging with addiction medicine services. They will complete the following activities:

  • Physical exam
  • Labs including drug screening
  • Pulmonary function testing (PFT)
  • Exercise testing (6MWD)
  • Echocardiography
  • Right heart catheterization (RHC)
  • Questionnaires related to their disease

Participants will be in the study for about six months.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

20

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Samantha Ruimy, MS
  • 전화번호: 503-494-0724
  • 이메일: ruimy@ohsu.edu

연구 연락처 백업

  • 이름: Allyson Knapper, MD
  • 전화번호: 503-494-5531
  • 이메일: knapper@ohsu.edu

연구 장소

    • Hawaii
      • Honolulu, Hawaii, 미국, 96813
        • The Queen's Medical Center
        • 연락하다:
        • 수석 연구원:
          • Gehan Devendra, MD
    • Oregon
      • Portland, Oregon, 미국, 97239
        • Oregon Health & Science University
        • 연락하다:
        • 연락하다:
          • Samantha Ruimy, MS
          • 전화번호: 5034940724
          • 이메일: ruimy@ohsu.edu
        • 수석 연구원:
          • Jeffrey C Robinson, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age ≥ 18 years
  • Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum mean PA pressure of 20 mmHg, PVR of ≥ 2 Wood units and pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of Meth-APAH as defined by patient verbally confirming exposure or having positive toxicology testing for methamphetamine within 5 years of PAH diagnosis
  • Symptomatic PAH classified as WHO FC II or III
  • Diagnosis of PAH within 12 months of screening and on stable doses of a ERA and PDE5i combination of background PAH therapies and diuretics (if any) for at least 90 days prior to screening
  • 6MWD ≥ 150 m completed at screening visit
  • Females of childbearing potential must meet the following criteria: Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; Agree to ongoing pregnancy testing (either urine or serum) during the course of the study and until 8 weeks after the last dose of the study drug; If sexually active with a male partner, use highly effective contraception without interruption for at least 28 days prior to starting the investigational product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment; Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
  • Male participants must meet the following criteria: Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy; Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
  • Ability to adhere to study visit schedule and understand and comply with all protocol requirements
  • Ability to understand and provide documented informed consent

Exclusion Criteria:

  • Diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis- associated PAH, collagen vascular disease- associated PAH, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis
  • Hgb at screening above gender-specific ULN, per local laboratory test
  • Uncontrolled systemic hypertension as evidenced by sitting systolic BP > 180 mmHg or sitting diastolic BP > 110 mmHg during the Screening Visit after a period of rest
  • Baseline systolic BP < 90 mmHg at screening
  • Pregnant or breastfeeding women
  • Any of the following clinical laboratory values at the Screening Visit: eGFR < 30 mL/min/1.73 m2 (as defined by MDRD equation), serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels > 3 × ULN, platelet count < 50,000/mm3 (< 50.0 × 109/L)
  • Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented informed consent
  • Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept
  • History of pneumonectomy
  • Pulmonary function test values of forced vital capacity < 60% predicted within 1 year prior to the Screening Visit
  • Stopped receiving any PH chronic general supportive therapy (e.g., diuretics, oxygen, anticoagulants, and digoxin) within 60 days prior to the Screening Visit
  • Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the Screening Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
  • Untreated more than mild obstructive sleep apnea
  • History of known pericardial constriction
  • History of restrictive cardiomyopathy
  • History of atrial septostomy within 180 days prior to the Screening Visit
  • Personal or family history of long QT syndrome or sudden cardiac death
  • Left ventricular ejection fraction < 50% documented by a historical ECHO or cardiac MRI within the last 12 months prior to screening (if there is more than one assessment of LVEF, the value from the most recent measurement should be used in assessing eligibility)
  • Coronary artery disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the Screening Visit
  • Cerebrovascular accident within 3 months prior to the Screening Visit
  • Acutely decompensated left heart failure within 30 days prior to the Screening Visit, as per investigator assessment
  • Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
  • Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, and vasopressin) within 30 days prior to the Screening Visit
  • Active malignancy with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or prostate cancer that is not currently or expected, during the study, to be treated with radiation therapy, chemotherapy, and/or surgical intervention, or hormonal treatment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Sotatercept with addiction medicine services

Sotatercept given in coordination with addiction medicine services

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Treatment response in methamphetamine-associated PAH
기간: 24 weeks

The main hypothesis is that the addition of sotatercept to standard background therapy and addiction medicine services will improve treatment response in meth-APAH, as measured by the echocardiographic parameter TAPSE divided by RVSP (mm/mmHg).

24 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Jeffrey C Robinson, MD, Oregon Health and Science University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2028년 9월 1일

연구 완료 (추정된)

2028년 11월 30일

연구 등록 날짜

최초 제출

2026년 8월 6일

QC 기준을 충족하는 최초 제출

2026년 11월 11일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • STUDY00028866
  • 103326 (기타 보조금/기금 번호: Merck Sharp & Dohme, LLC)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified data may be shared with qualified investigators upon request. Requests for access should include a brief description of the proposed research objectives, anticipated use of the data, and plans for data security and confidentiality. Data sharing will be considered for researchers with a legitimate scientific purpose, provided the proposed use is consistent with participant consent, applicable regulatory requirements, and institutional policies.

IPD 공유 기간

IPD and supporting information will be available from the date of results publication to ten years post-publication.

IPD 공유 액세스 기준

All requests will be reviewed by the Principal Investigator, who will evaluate whether: (1) the proposed use is appropriate and scientifically justified; (2) the requested data are necessary for the stated purpose; (3) the proposed use is consistent with participant consent and IRB requirements; and (4) adequate measures are in place to protect data confidentiality and security. Approved recipients may be required to execute a data use agreement prior to receiving study data.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .